

# *The ISGIDAR NEWSLETTER*

VOL. 25, NO. 1

April, 1999

---

## CORRESPONDENCE

<b>ABOUT ISGIDAR:</b> <i>(President of ISGIDAR)</i>	<b>ABOUT ISGIDAR NEWSLETTER:</b> <i>(Secretary of ISGIDAR)</i>
Patrick M. Beardsley, Ph.D. Medical College of Virginia Dept. of Pharmacology and Toxicology P.O. Box 980613 410 North 12th St. Smith Bldg. #756A Richmond, VA 23298-0613 tel: (804) 828-5185 email: <a href="mailto:pbeardsl@hsc.vcu.edu">pbeardsl@hsc.vcu.edu</a>	James P. Zacny, Ph.D. Dept. of Anesthesia & Critical Care MC4028 The University of Chicago 5841 S. Maryland Avenue Chicago, IL 60637 tel: (773) 702-9920 email: <a href="mailto:zacn@midway.uchicago.edu">zacn@midway.uchicago.edu</a>

---

## INDEX

[STUDENT TRAVEL AWARD](#)

[ISGIDAR LUNCHEON](#)

[ISGIDAR DISCUSSION LIST](#)

[RECENT PUBLICATIONS FROM OUR MEMBERS](#)

[POSITIONS AVAILABLE](#)

---

## **1999 ISGIDAR SCIENTIFIC MEETING - ACAPULCO, MEXICO**

The 1999 annual ISGIDAR Scientific Meeting will be held Saturday 12 June 1999 at the Acapulco Princess Resort (Princessa 1 meeting room) in Acapulco, Mexico. As usual, the meeting will be held as a satellite session immediately preceding the annual scientific meeting of the College on Problems of Drug Dependence. ISGIDAR

registration will begin at 8:30 am. The registration fee is \$50; this is a necessary increase from last year to cover the meeting costs (ISGIDAR is not getting rich by charging this registration fee - it hopes to break even). There will be two coffee breaks with the first break at the beginning of the session in which there will be a limited number of pastries. Luncheon will also be held and will cost from \$12-\$15 (see below). Paper presentations will be scheduled between 9 am and 5 pm, and the business meeting will be held from 5 to 5:30 pm.

**A couple of notes about this year's meeting:** We are especially pleased to announce that **Dr. Joseph Brady**, currently Professor of Psychiatry at the Johns Hopkins University School of Medicine, has accepted an invitation to address ISGIDAR. Also on the program there will be a small **symposium** on the proper control procedures for accessing the specificity of potential drug abuse medications. Many of ISGIDAR members are involved with developing medications to treat drug abuse disorders and this symposium should be particularly timely and interesting. Our **business meeting** this year is particularly important for we will be electing new officers. Members should make an extra attempt to attend the business meeting for this reason alone. Other topics for discussion during the business meeting will at least include the status of recent applicants as members as well as the membership process in general. If you would like to include other specific business topics please email them to Patrick Beardsley @ pbeardsl@hsc.vcu.edu.

All are highly encouraged to present data at this year's meeting. It is likely that attendance will be down from last year because we are meeting at a foreign site so the atmosphere will be even more intimate and informal than last year. To **present a paper** at the ISGIDAR meeting, please send an abstract by **May 20, 1999** to Patrick Beardsley at the address listed above. Abstracts should conform generally to the format used for presentations at CPDD but need not be on the CPDD abstract form nor is it necessary for them to fit into the "CPDD abstract box". Please note that papers submitted to ISGIDAR should not also be presented at CPDD. The amount of time available for each talk will depend on the number of papers submitted but will not be less than 20 minutes.

---

## **1999 TRAVEL AWARD:STUDENT PAPER COMPETITION**

ISGIDAR will again sponsor a Student Paper Competition Award for a new investigator to present a paper on drug self-administration research. Up to \$500 in reasonable and documented travel costs will be paid to the winner to present a paper

at ISGIDAR. Payment will be made upon submission of travel receipts to the ISGIDAR Treasurer. Those who do not receive the award, but who receive good reviews will be encouraged to present their papers at the ISGIDAR meeting. Submission deadline: May 20, 1999.

**ELIGIBILITY:**

- Applicants must be enrolled in a graduate program and be working toward a doctorate or have received their doctorate within the last five years (after June 1, 1994).
- Applicants who are not ISGIDAR members must be sponsored by an ISGIDAR member. The research to be reported at ISGIDAR must not already be published in its entirety.

**MANUSCRIPT REQUIREMENTS:**

- Papers should not be more than 10 pages excluding figures and references.
- 

The length and scope of the paper should be consistent with a 20-25 minute slide presentation.

- 
- Please include paper title, name, address, phone number and author's signature on the cover page of the manuscript. The signature and typed name of the author's sponsor should also appear on the cover page after a statement indicating that the applicant made a significant scientific contribution to the research. Submit four copies, double-spaced.

**REVIEW:**

Each manuscript will be independently reviewed by the ISGIDAR officers for originality, scientific contribution, methodology and clarity. Blind review is possible upon request. Reviewers will not participate in the review of papers from their own institution.

**SUBMIT MANUSCRIPTS TO: Patrick M. Beardsley, Ph.D.,**  
Medical College of Virginia, Dept. of Pharmacology & Toxicology, P.O. Box  
980613, 410 North 12th St., Smith Bldg. #756A, Richmond, VA 23298-0613

---

**ISGIDAR LUNCHEON**

We are again arranging to have lunch catered by the hotel, so that we can eat together and continue discussions from the morning session. The luncheon will be held in the Princessa 2 meeting room at the hotel. The lunch will cost about \$12-15 per person. Because in past years we have had difficulty estimating the number of people wanting lunch, which has resulted in some cases in large drains in the ISGIDAR treasury and in other cases in pleading and begging with hotel staff, we are asking that those wishing to join us for the ISGIDAR lunch indicate in advance, preferably by email (but you can use snail mail or fax if need be), to Patrick Beardsley at the address below. Please let the various members of your lab who will be attending ISGIDAR, but who might not receive the Newsletter, know about lunch. While there will be a limited number of seats available for those failing to indicate in advance their desire for lunch, these will be strictly limited and will be available on a first come first serve basis. Luncheon requests to:

[pbeardsl@hsc.vcu.edu](mailto:pbeardsl@hsc.vcu.edu) OR via snail mail:

**Patrick M. Beardsley, Ph.D.**, Medical College of Virginia, Dept. of Pharmacology & Toxicology, P.O. Box 980613, 410 North 12th St., Smith Bldg. #756A, Richmond, VA 23298-0613; FAX: (804) 828-2117

---

## **ISGIDAR Internet Discussion List** **"ISGIDAR-L@lists.vcu.edu"**

Our ISGIDAR Discussion/News Group is again active. The President of ISGIDAR had sent out the invitation below, via email, to all members of ISGIDAR *given the email addresses available in the ISGIDAR database at the time*. Many of these addresses were incorrect because LISTSERVER error messages were returned. If you wish to receive discussions via this discussion group please follow the directions below contained in the copy of Patrick's original emailing. We're sorry if you didn't receive this original invitation.

*Copy of the original email invitation:*

Through the able assistance of Jonathan Kamien we have reestablished the ISGIDAR Discussion List. You are being contacted because you were either a previous subscriber to this newsgroup, you are an ISGIDAR member, or you have attended a recent ISGIDAR meeting. We apologize if you have received this message more than once. If you are interested in subscribing to the new ISGIDAR Discussion List, please send an email message to the following address: [listserv@lists.vcu.edu](mailto:listserv@lists.vcu.edu)



prevents cocaine's reinforcing and toxic effects in rats. *Proceedings of the National Academy of Sciences* 95, 10176-10181.

- Briscoe, R.J. and Gauvin, D.V. (1999) Effects of ethanol hangover on the operant self-administration of cocaine in the rat. *Alcohol* 17, 41-45.
- Briscoe, R.J., Baird, T.J., Lerner, M., Brackett, D. and Gauvin, D.V. (1999) Altered cocaine-induced cardiovascular responses in awake freely moving rats during acute ethanol withdrawal. *Alcohol* (in press).

Dr. Nick E. Goeders

P.O. Box 33932

Department of Pharmacology &  
Therapeutics

Shreveport, LA 71130-  
3932

LSU Medical Center

[ngoede@lsu.edu](mailto:ngoede@lsu.edu)

- Goeders, N.E., B.D. Irby, C.C. Shuster and G.F. Guerin. Tolerance and sensitization to the behavioral effects of cocaine in rats: relationship to benzodiazepine receptors. *Pharmacol. Biochem. Behav.* 57: 43-56, 1997.
- Goeders, N.E. A neuroendocrine role in cocaine reinforcement. *Psychoneuroendocrinology* 22: 237-259, 1997.
- Simar, M.R., D. Saphier and N.E. Goeders. Dexamethasone suppression of the effects of cocaine on adrenocortical secretion in Lewis and Fischer rats. *Psychoneuroendocrinology* 22: 141-153, 1997.
- Goeders, N.E. Stress, the HPA axis, and vulnerability to drug abuse. *NIDA Research Monograph, Laboratory Behavioral Studies of Vulnerability to Drug Use*, C.L. Wetherington and J.L. Falk, eds., NIH publication number 98-4122, pp 83-104, 1998.
- Mantsch, J.R. and N.E. Goeders. Generalization of a restraint-induced discriminative stimulus to cocaine in rats. *Psychopharmacology* 135: 423-426, 1998.
- Goeders, N.E. and G.F. Guerin. Ketoconazole reduces low dose cocaine self-administration in rats. *Drug Alcohol Dependence* 53: 67-77, 1998.
- Mantsch, J.R., D. Saphier and N.E. Goeders. Corticosterone facilitates the acquisition of cocaine self-administration in rats: opposite effects of the glucocorticoid receptor agonist, dexamethasone. *J. Pharmacol. Exp. Ther.* 287: 72-80, 1998.
- Ikemoto, S. and N.E. Goeders. Microinjections of dopamine agonists and cocaine elevate plasma corticosterone: Dissociation effects among the ventral and dorsal striatum and medial prefrontal cortex. *Brain Research* 814: 171-178, 1998.
- Mantsch, J.R. and N.E. Goeders. Ketoconazole blocks the stress-induced reinstatement of cocaine-seeking behavior in rats: relationship to the discriminative stimulus effects of cocaine. *Psychopharmacology* (in press) 1999.
- Mantsch, J.R. and N.E. Goeders. Ketoconazole does not block cocaine discrimination of the cocaine-induced reinstatement of cocaine-seeking behavior. *Pharmacology, Biochemistry and Behavior* (in press) 1998.

Suzette M. Evans, Ph.D.

1051 Riverside Drive, Unit 66

Department of Psychiatry

New York, NY, 10032

College of Physicians and  
Surgeons of Columbia University  
and Research Scientist IV, The  
New York State Psychiatric  
Institute

[se18@mailhub.cc.columbia.edu](mailto:se18@mailhub.cc.columbia.edu)

- Levin, F.R., Evans, S.M. and Kleber, H.D. Prevalence of adult attention deficit hyperactivity disorder among cocaine abusers seeking treatment. *Drug Alcohol Depend.* 52: 15-25, 1998.
- Evans, S.M., Haney, M., Levin, F.R., Foltin, R. W. and Fischman, M.W. Mood and performance changes in women with premenstrual dysphoric disorder: Acute effects of alprazolam. *Neuropsychopharmacology* 19: 499-516, 1998.
- Evans, S.M., Levin, F.R., Fischman, M.W. and Foltin, R. W. Smoked cocaine self-administration in females and voucher incentives for abstinence. *J. Substance Abuse* 10: 143-162, 1998.
- Foltin, R.W. and Evans, S.M. The effects of d-amphetamine on cocaine and food intake. *Pharmacol. Biochem. & Behav.* 62: 457-464, 1999.
- Evans, S.M. and Griffiths, R.R. Caffeine withdrawal: A parametric analysis of caffeine dosing conditions. *J. Pharmacol. Exp. Ther.* 289: 285-294, 1999.
- Evans, S.M., Foltin, R.W. and Fischman, M.W. Food "cravings" and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. *Appetite* (in press).
- Evans, S.M., Haney, M., Fischman, M.W. and Foltin, R. W. Limited sex differences in response to binge smoked cocaine use in humans. *Neuropsychopharmacology* (in press).

Robert L. Balster, Ph.D.

P.O. Box 980613  
410 North 12th Street  
Smith Bldg., #756A

Department of Pharmacology &  
Toxicology

Richmond, VA 23298-  
0310

Medical College of Virginia

[balster@hsc.vcu.edu](mailto:balster@hsc.vcu.edu)

- Nicholson, K.L., Jones, H.E. and Balster, R.L. Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine. *Behavioural Pharmacology* 9:231-243, 1998.
- Wiley, J.L., Dance, M.E. and Balster, R.L. Preclinical evaluation of the reinforcing and discriminative stimulus effects of agomelatine (S-20098), a melatonin agonist. *Psychopharmacology* 140:503-509, 1998.

Stephen J. Heishman, Ph.D.

5500 Nathan Shock Drive

Clinical Pharmacology

Baltimore, MD 21224

NIDA Addiction Research Center

[sheish@intra.nida.nih.gov](mailto:sheish@intra.nida.nih.gov)

- Heishman, S. J. (1998). What aspects of human performance are truly enhanced by nicotine? *Addiction*, 93, 317-320.
- Fant, R. V., Heishman, S. J., Bunker, E. B., & Pickworth, W. B. (1998). Acute and residual effects of marijuana in humans. *Pharmacology Biochemistry and Behavior*, 60, 777-784.
- Henningfield, J. E., & Heishman, S. J. (1998). Behavioral toxicology of nicotine. In N. L. Benowitz (Ed.), *Nicotine safety and toxicity* (pp. 133-146). New York: Oxford.
- Heishman, S. J., Singleton, E. G., & Crouch, D. J. (1998). Laboratory validation study of Drug Evaluation and Classification program: Alprazolam, d-amphetamine, codeine, and marijuana. *Journal of Analytical Toxicology*, 22, 503-514.
- Bell, S. L., Taylor, R. C., Singleton, E. G., Henningfield, J. E., & Heishman, S. J. (1999). Smoking after nicotine deprivation enhances cognitive performance and decreases tobacco craving. *Nicotine and Tobacco Research*, 1, 45-52.
- Heishman, S. J., & Henningfield, J. E. (in press). Is caffeine a drug of dependence? Criteria and comparisons. In B. S. Gupta & U. Gupta (Eds.), *Caffeine and behavior: Current views and research trends* (pp. 139-152). Boca Raton, FL: CRC Press.
- Heishman, S. J., Weingartner, H. J., & Henningfield, J. E. (in press). Selective deficits in reflective cognition of polydrug abusers: Preliminary findings. *Psychology of Addictive Behaviors*.
- Rothman, R. B., Gorelick, D. A., Heishman, S. J., Eichmiller, P. R., Hill, B. H., Norbeck, J., & Liberto, J. G. (in press). An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. *Journal of Substance Abuse Treatment*.

Jonathan Katz, Ph.D.

P.O. Box 5180

NIDA Intramural Research Program Baltimore, Maryland 21224

[JKatz@irp.nida.nih.gov](mailto:JKatz@irp.nida.nih.gov)

- Zhang, C., Izenwasser, S., Katz, J.L., Terry, P., and Trudell, M.L. Synthesis and dopamine transporter affinity of the four stereoisomers of (◆)-2-methoxycarbonyl-7-methyl-3-phenyl-7-azabicyclo[2.2.1]heptane. *Journal of Medicinal Chemistry*, 41: 2430-2435, 1998.
- Lomenzo, S.A., Izenwasser, S., Katz, J.L., and Trudell, M.L. The effects of alkyl substituents at the 6-position of cocaine analogues on dopamine transporter binding affinity and dopamine uptake inhibition. In: A.H. Newman (Ed.). *The Dopamine Transporter as a Molecular Target for the Development of Cocaine Abuse Therapeutics*, *Medicinal Chemistry Research*, 8: 35-42, 1998.
- Bergman, J. and Katz, J.L. Behavioral Pharmacology of Cocaine. In: S.T. Higgins and J.L. Katz (Eds.). *Cocaine Abuse Research: Pharmacology, Behavior, and Clinical Applications*. San Diego: Academic Press, 1998, pp. 51-79.



- Katz, J. L., Izenwasser, S., Kline, R.H., Allen, A.C., Newman, A.H. Novel 3 -diphenyl-methoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. *Journal of Pharmacology and Experimental Therapeutics*, 288: 302-315, 1999.
- Tolliver, B.K., Newman, A.H., Katz, J.L., Ho, L.B., Fox, L.M., Hsu, K., Jr., and Berger, P.S. Behavioral and neurochemical effects of dopamine transporter ligands alone and in combination with cocaine: Characterization of 4-chlorobenzotropine in vivo. *Journal of Pharmacology and Experimental Therapeutics*, 289: 110-122, 1999.

## POSITIONS AVAILABLE

### **MEDICAL COLLEGE OF VIRGINIA, DEPARTMENT OF PHARMACOLOGY & TOXICOLOGY**

Postdoctoral research positions are available in **laboratory animal behavioral pharmacology**. Positions are possible utilizing almost any behavioral pharmacological approach to the study of the behavioral and/or neurochemical mechanisms mediating the activity of the drugs of abuse. Ongoing studies utilize mice, rats, and rhesus monkeys in locomotor activity, discrimination, self-administration, and other operant and respondent procedures involving all routes of systemic and central drug administration. Of particular current emphasis are studies involving the:

- pharmacology of dopamine D3 receptor ligands
- pharmacology of excitatory amino acid agents
- development of medications for the treatment of drug-dependency disorders
- pharmacology of behaviorally-active inhalation agents
- effects of chemicals on the probability of relapse to cocaine and heroin self-administration

Many opportunities exist for collaborating with other researchers in the department who have major research foci upon the stimulants and hallucinogens, cannabinoids, nicotine, and the opiates. Send vita, letter of interest, and names and telephone numbers of 2 references to: **PATRICK M. BEARDSLEY, PH.D. OR ROBERT L. BALSTER, PH.D.**; Medical College of Virginia, Department of Pharmacology, P.O. Box 980613, Richmond, VA 23298-0613. (804) 828-5185.

### **LOUISIANA STATE UNIVERSITY MEDICAL CENTER, DEPARTMENT OF PHARMACOLOGY AND TOXICOLOGY**

Stress, the HPA Axis and Cocaine Reinforcement. Postdoctoral Positions available immediately on NIDA-supported projects investigating the behavioral neurobiology of cocaine, with special emphasis on receptor systems and brain regions associated with stress and the activation of the hypothalamic-pituitary-adrenal axis. In particular, the effects of environmental stress and stress-related hormones on the acquisition and maintenance of intravenous cocaine self-administration, as well as the effects of stress

on drug-induced changes in cocaine self-administration and other behavioral effects of the drug, will be investigated. State of the art procedures including operant behavioral pharmacology, homogenate receptor binding and quantitative receptor autoradiography, and in vivo microdialysis and neurochemistry are available. Candidates must have a Ph.D. in Pharmacology, Neuroscience, Psychology or a related discipline with relevant laboratory experience. Salary will be commensurate with postdoctoral experience. Please send curriculum vitae and the names of three references to: Dr. Nick E. Goede, Department of Pharmacology & Therapeutics, LSU Medical Center, P.O. Box 33932, Shreveport, LA 71130-3932. [E-mail: [ngoede@lsuic.edu](mailto:ngoede@lsuic.edu)]

#### **NIDA INTRAMURAL RESEARCH PROGRAM**

Postdoctoral Research in Drug Abuse. The National Institute on Drug Abuse (NIDA) has a postdoctoral position available in Clinical Pharmacology. The research program involves clinical studies on 1) attentional deficits and tobacco craving observed during nicotine withdrawal and 2) cognitive and psychomotor effects of marijuana and other drugs. The candidate must have a Ph.D., and a background in cognitive or experimental psychology or behavioral pharmacology is highly desirable. Candidates must be U.S. citizens or permanent residents. Salary is commensurate with postdoctoral experience. Applicants should submit a curriculum vitae and names of three references to: Stephen J. Heishman, Ph.D., Clinical Pharmacology, NIDA/IRP, 5500 Nathan Shock Drive, Baltimore, MD 21224. Questions about the position may be addressed to Dr. Heishman (410-550-1547). NIDA is an equal opportunity employer and encourages applications from women and minorities.

#### **UNIVERSITY OF FLORIDA, DEPARTMENT OF PSYCHOLOGY**

Post-Doctoral Position Available Immediately. Department of Psychology, University of Florida. Immediate opening for a Post-Doctoral Fellow in the Behavioral Pharmacology Laboratory of Dr. Frans van Haaren. Expertise in drug discrimination and drug self-administration in rats is required, interest in sex differences an advantage. The position is sponsored through an Institutional Training Grant from the National Institute of Dental Research (Dr. Marc Heft, Program Director). The stipend is determined by the number of years of relevant post-doctoral experience at the time of appointment (range \$22,000 - \$34,000). Send curriculum vitae and names of three references to: Dr. Frans van Haaren, Department of Psychology, University of Florida, Gainesville, FL 32611-2250. Tel: (352) 392-0601, x292, e-mail: [haaren@psych.ufl.edu](mailto:haaren@psych.ufl.edu)

**UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES, DEPARTMENT OF PHARMACOLOGY & TOXICOLOGY**

NIH-funded postdoctoral positions. Two positions available to develop monoclonal antibody-based medications for drug abuse. Candidates should have training or research interest in pharmacokinetics/pharmacodynamics, analytical biochemistry or a related field. Contact Michael Owens, PhD at [owenssamuelm@exchange.uams.edu](mailto:owenssamuelm@exchange.uams.edu). A third position to study the role of pharmacokinetics in determining the behavioral effects of dextromethorphan. Experience with one of the following areas essential: Pharmacokinetic studies in rodents, HPLC techniques, or pharmacokinetic modeling. Contact William D. Wessinger, PhD at [wdwessinger@life.uams.edu](mailto:wdwessinger@life.uams.edu). For more information on all of these positions write to Department of Pharmacology & Toxicology, University of Arkansas for Medical Sciences, Slot 611, 4301 W. Markham St., Little Rock, AR 72205 or visit [our website](#). EOE.

**MCLEAN HOSPITAL / HARVARD MEDICAL SCHOOL**

Postdoctoral fellowship. A postdoctoral position is currently available for research in the Behavioral Pharmacology Laboratory at McLean Hospital / Harvard Medical School. The research includes in vivo pharmacological studies, primarily employing drug self-administration and drug discrimination procedures. We are especially interested in hard-working individuals with a strong background in pharmacology and some previous experience with behavioral measurement using operant or observational procedures. Compensation follows NIH guidelines for postdoctoral training and includes full health-care benefits. For further information, please inquire at [bpfarm@hms.harvard.edu](mailto:bpfarm@hms.harvard.edu) or write to Jack Bergman, Ph.D. / 115 Mill Street / Belmont MA 02478.

**LSU MEDICAL CENTER - NEW ORLEANS, DEPARTMENT OF PHARMACOLOGY**

Postdoctoral Fellow Position in behavioral pharmacology to study the discriminative stimulus, reinforcing, antinociceptive, ventilatory and other effects of benzodiazepines, opioids and psychomotor stimulants in normal and dependent non-human subjects. Applicants should have a Ph.D. in pharmacology, psychology, or neuroscience. Send CV, description of research interests and the names of three references to C.P. France, Ph.D., Department of Pharmacology, LSU Medical Center, 1901 Perdido Street, New Orleans, LA 70112-1393 ([cfranc@lsuonc.edu](mailto:cfranc@lsuonc.edu)). AA/ADA/EOE.